key: cord-0901366-bv3b7bbm authors: Holmes, G. Alden; Desai, Mansee; Limone, Brittanya; Love, Justin; Tawfik, Melanie; Wong, Lulu; Furukawa, Betsy title: A Case Series of Cutaneous COVID-19 Vaccine Reactions at Loma Linda University Department of Dermatology date: 2021-08-18 journal: JAAD Case Rep DOI: 10.1016/j.jdcr.2021.07.038 sha: ca3f347fac4fbc86cc75fd1388d115c3692f5c4b doc_id: 901366 cord_uid: bv3b7bbm nan To date, the United States' Food and Drug Administration (FDA) has issued emergency use Center were Pfizer and Moderna-novel messenger RNA vaccines. The EUA for the Pfizer 32 vaccine was issued based on a randomized, controlled trial demonstrating a less than 1.2% rate 33 of local side effects rated grade three or higher including redness, swelling, and pain. 3 to chronic dermal hypersensitivity reaction producing a nummular dermatitis was made. 148 Tacrolimus ointment was prescribed for his eyelids, and fluocinonide ointment for his forearms. 149 The patient noted complete resolution within two to three weeks. (Table 1) The advisory committee on immunization 218 practices' interim recommendation for use of moderna covid-19 vaccine -united states Systemic Reactions, Adverse Events, and Serious Adverse Events Adverse Events, and Serious Adverse Events: Moderna 228 COVID-19 Vaccine COVID-19 vaccine research and development: ethical issues CDC COVID-19 Response Team, Food and Drug Administration Maintaining safety with sars-cov-2 vaccines Acute allergic reactions to mrna 240 covid-19 vaccines COVID arm": A reaction to 242 the Moderna vaccine Cutaneous reactions reported after 19 vaccination: A registry-based study of 414 cases Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine 247 Overview and Safety. Pfizer-BioNTech COVID-19 EUA Fact Sheet for Recipients and Centers for Disease Control and Prevention. Moderna COVID-19 Vaccine Overview and Moderna COVID-19 EUA Fact Sheet for Recipients and Caregivers Immediate and delayed allergic contact reactions to polyethylene glycol Allergic contact dermatitis to polyethylene 256 glycol and nitrofurazone Successful SARS-CoV-2 vaccine allergy risk-264 management: the experience of a large Italian University Hospital Allergic reactions and anaphylaxis to lnp-based covid-19 vaccines European Medicines Agency Committee for Medicinal Products for Human Use COVID-19 mRNA vaccine (nucleoside-modified) Assessment Report Selective severe anaphylactic reaction due to ketorolac 273 tromethamine without nonsteroidal anti-inflammatory drug intolerance